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Abstract
Background: Long noncoding RNA HOX antisense intergenic RNA myeloid 1 (HOTAIRM1) has been characterized
as a critical factor in all-trans retinoic acid (ATRA)-induced differentiation of acute promyelocytic leukemia (APL)
cells. However, the essential transcription factor for gene expression of HOTAIRM1 is still unknown.
Findings: Chromatin immunoprecipitation (ChIP) assays revealed that PU.1 constitutively bound to the regulatory
region of HOTAIRM1. Co-expression of PU.1 led to the transactivation of the regulatory region of HOTAIRM1 in a
reporter assay. Detailed analysis showed that two PU.1 motifs, which were located around +1100 bp downstream
of the transcriptional start site of the HOTAIRM1 promoter, were responsible for the PU.1-dependent transactivation.
The induction of HOTAIRM1 by ATRA was dependent on PU.1, and ectopic expression of PU.1 significantly up-
regulated HOTAIRM1. Furthermore, low HOTAIRM1 expression was observed in APL cells, which was attributed to
the reduced PU.1 expression rather than the repression by PML-RARα via the direct binding.
Conclusion: PU.1 directly activates the expression of HOTAIRM1 through binding to the regulatory region of
HOTAIRM1 during granulocytic differentiation. The reduced PU.1 expression, rather than PML-RARα itself, results in
the low expression of HOTAIRM1 in APL cells. Our findings enrich the knowledge on the regulation of lncRNAs and
the underlying mechanisms of the abnormal expression of lncRNAs involved in APL.
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Introduction
Recently, it has become increasingly clear that long non-
coding RNAs (lncRNAs) function as a class of versatile
regulators through interaction with DNA, RNA, and
proteins to modulate gene expression [1–3]. Extensive
studies have focused on the functions of lncRNAs in
cells and demonstrated that lncRNAs modulate tran-
scriptional regulation, regulate protein activities, play
structural or organizational roles, and serve as precur-
sors to small RNAs [4–7]. Thus, aberrant expression of
lncRNAs is associated with disease development. How-
ever, the molecular mechanisms underlying the regula-
tion of lncRNAs are still largely unknown.
HOX antisense intergenic RNA myeloid 1 (HOTAIRM1)
is a myeloid-specific lncRNA, which is transcribed be-
tween the HOXA1 and HOXA2 genes. Functional studies
have revealed that HOTAIRM1 is essential for myeloid dif-
ferentiation. HOTAIRM1 knockdown impairs all-trans ret-
inoic acid (ATRA)-driven granulocytic differentiation and
attenuates the expression of differentiation-related genes
including ITGAM, CD18, HOXA1, and HOXA4 [8].
HOTAIRM1 knockdown can also result in a reduction of
ATRA-induced cell cycle arrest at the transition from G1
to S phase [9]. A recent clinical study has investigated the
clinical impact of HOTAIRM1 and demonstrated that high
HOTAIRM1 expression is associated with poor prognosis
in intermediate-risk acute myeloid leukemia (AML) pa-
tients [10]. In addition, the low expression of HOTAIRM1
is observed in acute promyelocytic leukemia (APL) [10].
Despite the importance of HOTAIRM1 in myeloid differ-
entiation, the critical transcription factor regulating the ex-
pression of HOTAIRM1 has not been identified to date.
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Transcription factor PU.1 is a master regulator in the
control of myeloid differentiation [11–13]. PU.1 tran-
scriptionally regulates the genes necessary for myeloid
differentiation of granulocytes and monocytes, including
granulocyte/macrophage colony-stimulating factor re-
ceptor (GM-CSFR) [14–16], CD11b [17], CD18 [18], and
myeloperoxidase [19]. A tightly regulated level of PU.1 is
essential for normal hematopoiesis. Dysregulation of
PU.1 can lead to the development of AML [20–22]. Our
previous work [23, 24] showed that, in the development
of APL, both the targets and the expression level of
PU.1 are inhibited by the oncogenic PML-RARα fusion
protein, which is generated by the chromosomal trans-
location, t(15;17). Afterwards, a series of PU.1-regulated
genes, such as genes encoding HCK [25] and immuno-
proteosomes [26], have been reported to contribute to
APL leukemogenesis due to the dysregulation of their
expression. During the treatment of APL, ATRA restores
the expression of both PU.1 and its downstream target
genes by degrading PML-RARα, thus relieving the differ-
entiation block [27–29]. Moreover, genome-wide binding
profiling of these APL-associated transcription factors,
e.g., PML-RARα and PU.1, has demonstrated that the
molecular consequences of these transcription factors
are undoubtedly complex, as they associate with and
likely regulate a relatively large number of diverse genes
accounting for as much as 10–15 % of the genome [30].
Those target genes include not only protein-coding genes
but also noncoding transcripts, especially lncRNAs.
In this study, using chromatin immunoprecipita-
tion (ChIP) and luciferase reporter assays, we found
that PU.1 bound to the regulatory region of
HOTAIRM1 in vivo and transactivated this region,
which was mainly mediated through two PU.1 motifs
around +1100 bp downstream to the transcription
start site (TSS). Furthermore, PU.1 knockdown
down-regulated HOTAIRM1 and PU.1 overexpres-
sion increased HOTAIRM1. Finally, we revealed that
the reduced PU.1 expression was responsible for the
low HOTAIRM1 expression in APL cells.
Results
The induction of HOTAIRM1 upon ATRA treatment
requires intermediate protein synthesis
It has been shown that HOTAIRM1 is up-regulated in
APL cells upon exposure to ATRA and plays a critical
role in myeloid differentiation [8]. Since HOTAIRM1
has two variants, we designed variant-specific primers to
examine the expression of each variant in APL-derived
NB4 cells upon ATRA treatment. As shown in Fig. 1a,
HOTAIRM1 variant 2 was the major isoform that was
expressed both before and after ATRA treatment. By
comparison, HOTAIRM1 variant 1 was far less abundant
than variant 2. Both variants were up-regulated upon
ATRA treatment. To investigate whether the induction
of HOTAIRM1 was a direct effect of ATRA, NB4 cells
were pretreated with a translation inhibitor cyclohexi-
mide (CHX) for 30 min prior to the addition of ATRA
to interfere with the translation process of newly synthe-
sized proteins. As shown in Fig. 1b, CHX significantly
impaired the up-regulation of both HOTAIRM1 variants
by ATRA, suggesting that the induction of HOTAIRM1
requires newly synthesized intermediate protein(s).
PU.1 directly binds to the regulatory region of HOTAIRM1
To search for the newly synthesized regulatory factors
involved in the up-regulation of HOTAIRM1, we first
identified the regulatory region responsible for the tran-
scriptional regulation of HOTAIRM1, which can be de-
fined using binding profiles of H3K4me3 and H3K27Ac.
Due to the myeloid-specific expression of HOTAIRM1, we
chose CD14+ monocytes (a myeloid lineage) for the ana-
lysis. We utilized the chromatin immunoprecipitation
(ChIP)-seq data generated by the ENCODE Project Con-
sortium [31]. The binding profiles were displayed using
the UCSC Genome Browser (http://genome.ucsc.edu)
Fig. 1 The induction of HOTAIRM1 upon ATRA treatment requires the intermediate protein synthesis. a The expression levels of two HOTAIRM1
variants at different time points following 1 μM ATRA treatment in NB4 cells. b The expression levels of two HOTAIRM1 variants in NB4 cells
before and after ATRA treatment (1 μM) for 8 h, with or without 30 min CHX pretreatment (100 μg/mL). The relative expression level was
calculated relative to that of variant 1 at 0 h. An average of two control genes (GAPDH and ACTB) was used for normalization. The data represent
the mean of three replicates ± SD. *p < 0.05; **p < 0.01
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[32]. As shown in Fig. 2a, the enrichment of H3K4me3
and H3K27Ac binding was found to be located from
about −100 bp upstream of the transcription start site
(TSS) to approximately +1200 bp downstream of the
TSS. The data indicated that this region mediated the
transcription of HOTAIRM1 and this region was used
in the following experiment and analysis. We then
investigated the significantly enriched transcription
factor binding sites within this regulatory region of
HOTAIRM1 using Matinspector [33]. Interestingly, we
found eight putative binding sites for PU.1 (Fig. 2b),
which is a hematopoietic transcription factor involved
in myeloid differentiation and up-regulated upon ATRA
treatment. To analyze the binding of PU.1, we per-
formed ChIP assays in ATRA-treated NB4 cells. We de-
signed six primer pairs to search for the in vivo binding
of PU.1 around these eight PU.1-motif-containing sites.
The closely located motifs were investigated using the
same set of the primers. The primer pair “+600” cov-
ered motifs at +586 and +629 and the primer pair
“+1100” covered motifs at +1067 and +1123. The re-
gions upstream (−400) and downstream (+1600) of the
regulatory region and an irrelevant region (NC) were used
as negative controls. As shown in Fig. 2c, the position
around +1100 bp downstream to the TSS showed dramat-
ically significant enrichment of PU.1 binding in NB4 cells,
and this was far more noticeable than the other putative
sites. Additionally, we also detected the PU.1 binding in
another myeloid cell line, U937, which belongs to a differ-
ent AML subtype but can also undergo myeloid differenti-
ation upon ATRA treatment. The similar PU.1 binding
pattern was observed in ATRA-treated U937 cells, ruling
out cell line-specific phenomena. The data together indi-
cated that PU.1 directly bound to the regulatory region of
HOTAIRM1.
PU.1 transactivates HOTAIRM1 through the +1100 region
in the HOTAIRM1 promoter
To further investigate whether PU.1 transactivates the
regulatory region of HOTAIRM1 through the PU.1 bind-
ing sites identified above, we employed the luciferase re-
porter assay in HEK-293T cells, which lack endogenous
PU.1. We cloned a 1370 bp fragment of the regulatory
region of HOTAIRM1 spanning from −134 to +1237
into a luciferase reporter plasmid, which was designated
as pGL3-HOTAIRM1 (Fig. 3a). We also included one
mutant form of the complete regulatory region in which
the core sequences of PU.1 sites at +1067 and +1123
were mutated from GGAA to CCAA, and one truncated
construct spanning from −134 to +911 and lacking PU.1
sites on the +1100 region. As shown in Fig. 3b, co-
expression of PU.1 resulted in significant activation of
Fig. 2 PU.1 directly binds to the regulatory region of HOTAIRM1. a Genome browser screen shot of the HOTAIRM1 locus. Input (GSM1003475), H3K4me3
(GSM1003536), and H3K27Ac (GSM1003559) ChIP-seq signals of CD14+ monocytes were displayed in the UCSC genome browser. b Schematic
representation of putative PU.1 binding sites around the promoter region of HOTAIRM1. c PU.1 ChIP-qPCR showing the enrichment of PU.1 in each
putative binding site and the negative site in NB4 or U937 cells upon ATRA treatment for 24 h. The data represent the mean of three replicates ± SD
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the full-length regulatory region of HOTARIM1. In contrast,
the transactivation ability of PU.1 on the regulatory region
of HOTAIRM1 was significantly reduced in both PU.1-
mutated and PU.1-truncated constructs (Fig. 3b). The
results indicated that PU.1 could transactivate the
HOTAIRM1 promoter, and PU.1 motifs at +1067 and
+1123 were essential for the transcriptional activation
of HOTAIRM1.
The induction of HOTAIRM1 is dependent on PU.1 during
granulocytic differentiation
Next, we investigated the dependency of HOTAIRM1 on
PU.1 in a hematopoietic context. To examine the in vivo
regulation by PU.1, we silenced PU.1 in NB4 cells, followed
by ATRA treatment for 24 h. To rule out off-target effects,
two siRNAs against PU.1 were used and their knockdown
efficiencies were around 63 and 74 %, respectively (Fig. 4).
As a positive control, ITGAM (encoding myeloid integrin
CD11b), whose expression is known to rely on PU.1 [17],
showed a significant reduction. We used HNRNPH1 as
negative control, as its expression level was not affected by
the PU.1 level. Both HOTAIRM1 variants were significantly
reduced in PU.1 knockdown cells compared with negative
control cells (Fig. 4), suggesting that PU.1 was essen-
tial for the expression of HOTAIRM1 during granulo-
cytic differentiation.
Additionally, we also detected the effect of arsenic tri-
oxide (ATO), another effective agent used in APL ther-
apy, on HOTAIRM1 expression. We found that ATO
had almost no effect on the expression levels of
HOTAIRM1 and PU.1 (Additional file 1: Figure S1), fur-
ther supporting the above observation that the induction
of HOTAIRM1 depended on the up-regulation of PU.1.
Low HOTAIRM1 expression is observed in APL cells, which
is attributed to the reduced PU.1 expression, rather than
the direct binding and repression by PML-RARα
Since HOTAIRM1 expression is up-regulated during
ATRA-induced granulocytic differentiation of APL cells,
we were interested in HOTAIRM1 expression in APL
cells. We first compared the expression of HOTAIRM1
between APL cells and non-APL cells using AML cell
lines. In APL patient-derived NB4 cells, the expression
abundancy of both HOTAIRM1 and PU.1 was signifi-
cantly lower than that in non-APL AML cells (U937 and
HL60) (Fig. 5a). To validate this finding in a large cohort
of patient samples, we utilized previously published tran-
scriptome data [34] to compare their expression between
APL patient samples and non-APL AML patient sam-
ples. As shown in Fig. 5b, compared to non-APL AML,
HOTAIRM1 was noticeably lower in APL patients,
which is consistent with a recent clinical study on AML
Fig. 3 PU.1 transactivates HOTAIRM1 through the +1100 region in the HOTAIRM1 promoter. a Schematic representation of pGL3-HOTAIRM1 as well
as its mutated and truncated forms. b PU.1-transactivated promoter activity of HOTAIRM1. Loss of major PU.1 binding sites significantly impaired PU.1
transactivation on the HOTAIRM1 promoter. The luciferase promoters were co-transfected with equal amount of the pcDNA3.1 or pcDNA3.1-PU.1
vector to HEK-293T cells. The data represent the mean of three replicates ± SD. *p < 0.05; **p < 0.01
Fig. 4 The induction of HOTAIRM1 is dependent on PU.1 during granulocytic differentiation. The expression of PU.1, HOTAIRM1, ITGAM, and
HNRNPH1 after non-targeting or PU.1 siRNA transfection in NB4 cells, with ATRA treatment for 24 h. An average of two control genes (GAPDH
and ACTB) was used for normalization. The data represent the mean of three replicates ± SD. *p < 0.05; **p < 0.01; ***p < 0.001
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patients [10]. Similarly, PU.1 was also lower in APL, sup-
porting the above cell line-based results.
Low expression of HOTAIRM1 in APL could be due
to several possibilities. First, since PML-RARα gener-
ally acts as a repressor on its direct target genes by
recruiting co-repressors, such as HDAC1, N-coR, and
SMRT [27], HOTAIRM1 expression might be repressed
by the direct PML-RARα binding. To test this possibil-
ity, we first examined whether PML-RARα could dir-
ectly bind to the regulatory region of HOTAIRM1
using ChIP-qPCR assays. As shown in Fig. 5c, there
was no enrichment of either PML or RARα binding
around the regulatory region of HOTAIRM1 in NB4
cells, indicating that PML-RARα did not directly bind
to the HOTAIRM1 promoter to repress its expression.
The luciferase reporter assay also showed that PML-
RARα had minimal impact on the promoter activity of
HOTAIRM1 (Fig. 5d). Both tests excluded the possibil-
ity of the direct binding and repression by PML-RARα.
Second, since we showed that HOTAIRM1 was a
PU.1 target gene and was activated by PU.1 (Figs. 2
and 3), and since PML-RARα is capable of repressing
PU.1-regulated genes [23], another possibility might
be that PML-RARα repressed PU.1-dependent transacti-
vation of HOTAIRM1. This possibility was ruled out by
the observation that PML-RARα led to a negligible change
Fig. 5 Low HOTAIRM1 expression is attributed to the reduced PU.1 expression. a HOTAIRM1 and PU.1 mRNA expression levels in representative
AML cell lines. b Low levels of HOTAIRM1 and PU.1 in APL patients, as compared with non-APL patients (GSE10358). c ChIP-qPCR showing the
binding of PML-RARα on the HOTAIRM1 promoter, the PU.1 promoter (as a positive control), and the negative site. d The effect of PML-RARα on
promoter activity of HOTAIRM1. The pGL3-HOTAIRM1 plasmid was co-transfected with 200 ng expression vectors (pcDNA3.1 alone, PML-RARα
alone, PU.1 alone, PU.1 and PML-RARα together, respectively) into HEK-293T cells. e The Pearson correlation between PU.1 and HOTAIRM1 expression
in an AML patient cohort (GSE10358). f The up-regulation of HOTAIRM1 after PU.1 overexpression. NB4 cells were harvested at 48 h post-transduction
with the MigR1 empty vector or the MigR1-PU.1 vector. The expression level of PU.1 was detected by western blotting. The mRNA expression
levels of HOTAIRM1 and ITGAM were detected by RT-qPCR. GAPDH was used for normalization. The data represent the mean of three
replicates ± SD. *p < 0.05; **p < 0.01
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in PU.1-mediated transactivation through the luciferase
reporter assay (Fig. 5d).
Third, low HOTAIRM1 expression could be attributed
to the reduced PU.1 expression in APL since PU.1 ex-
pression is repressed by PML-RARα due to disruption of
PU.1 autoregulation [23, 35]. To test this possibility, we
first examined the correlation between PU.1 and
HOTAIRM1 in a large cohort of AML patient samples
[34]. We found a significant positive correlation between
PU.1 expression and HOTAIRM1 expression (r = 0.493,
p < 2.2e−16) (Fig. 5e). To support this finding, we rescued
the PU.1 expression by over-expressing PU.1 in PML-
RARα-positive NB4 cells. With PU.1 ectopic expression,
HOTAIRM1 expression was increased more than five-
fold in NB4 cells (Fig. 5f ). This also provided an explan-
ation for the up-regulation of HOTAIRM1 in NB4 cells
upon ATRA treatment: ATRA restored the expression
of PU.1 [29] and then the up-regulated PU.1 transacti-
vated HOTAIRM1.
Taken together, the data suggested that low
HOTAIRM1 expression in APL cells was attributed to
the reduced PU.1 expression rather than repression by
PML-RARα via the direct binding.
Discussion
Recently, extensive studies have been carried out to
understand the functions of lncRNAs, but fewer studies
have focused on the regulation of lncRNAs. In this
study, we reveal that the transcription factor PU.1 con-
trols the expression of the lncRNA HOTAIRM1, which
acts as a critical noncoding regulator in ATRA-induced
granulocytic differentiation of APL cells. On the one
hand, we showed that HOTAIRM1 was not a direct
ATRA-responsive gene, and the observed up-regulation
of HOTAIRM1 induced by ATRA was a secondary event
that was dependent on the expression of PU.1 activated
by ATRA.
On the other hand, we observed low HOTAIRM1 ex-
pression in APL cells and revealed that low expression
was attributed to the reduced PU.1 expression, rather
than the direct binding and repression of PML-RARα.
To support these observations, we provided the evidence
that PU.1 constitutively bound to the regulatory region
of HOTAIRM1 to transactivate the promoter activity of
HOTAIRM1 and identified the two PU.1 motifs respon-
sible for the PU.1-dependent transactivation. These find-
ings enrich our knowledge on the regulation of lncRNAs
and the underlying mechanisms of the abnormal expres-
sion of lncRNAs involved in APL.
Our first contribution is identifying HOTAIRM1 as a
novel target of PU.1. This finding implicates that there
still exist unidentified PU.1 targets that are essential for
myeloid differentiation. To date, most of the known
PU.1 direct target genes participating in myeloid
differentiation belong to protein-coding genes [36]. To
the best of our knowledge, few have reported the role of
PU.1 in the modulation of lncRNAs during myeloid dif-
ferentiation. Our work presents an example of lncRNAs
as the PU.1 target. In addition to HOTAIRM1, there are
perhaps hundreds of lncRNA candidates potentially under
the transcriptional control of PU.1, among which some
are likely correlated with or necessary for myeloid differ-
entiation. Systematic approaches like ChIP-seq and RNA-
seq would be a powerful tool to globally identify these
PU.1 candidate targets. In addition, we also identified the
direct binding site of PU.1 at the +1100 downstream of
the TSS of the HOTAIRM1 promoter. It is worth men-
tioning that it was possible that the −122 region might
also have a partial impact on the promoter activity of
HOTAIRM1, although we focused on the +1067/+1123
locus in the luciferase reporter assay (Fig. 3b). The contri-
bution from the −122 region was probably much less than
the +1067/+1123 region, since the in vivo PU.1 binding
signals at the +1067/+1123 locus were markedly higher
than those at the −122 locus (Fig. 2c).
Second, our work suggests the role of HOTAIRM1 in
the PU.1-mediated regulation network during myeloid
differentiation. PU.1 regulates differentiation as well as
cell cycle and proliferation. For example, exogenous
PU.1 expression up-regulates endogenous PU.1 levels in
progenitor cells, which is achieved by the induction of
cell cycle lengthening, suggesting a positive feedback cir-
cuit between PU.1 and the cell cycle in the modulation
of myeloid differentiation [37]. PU.1 occupies the CDK6
gene promoter and directly stimulates CDK6 transcrip-
tion, coordinating proliferation and differentiation [38].
Our work found that HOTAIRM1 was transcriptionally
activated by PU.1 and their expression levels were sig-
nificantly correlated in AML patients. Interestingly,
HOTAIRM1 also regulates myeloid differentiation [8]
and cell cycle arrest [9]. In addition, HOTAIRM1 modu-
lates CD18 and ITGAM [8], which are known to be
transcriptionally controlled by PU.1 [17, 18]. These find-
ings suggest that HOTAIRM1 may participate in the
downstream PU.1-dependent transcription regulation
during myeloid differentiation. In another word,
HOTAIRM1 may act as a downstream effector of PU.1
by regulating myeloid differentiation-associated genes
and cell cycle-related genes.
Third, our research provides insights into the tissue
specificity of HOTAIRM1. Tissue specificity is a charac-
teristic of lncRNAs, which usually exhibit a more re-
stricted expression pattern than protein-coding genes
[39, 40]. Most recently, lncRNAs have been demon-
strated to be dynamically expressed during erythropoi-
esis and these erythriod-specific transcripts are under the
direct transcriptional control of core erythroid transcrip-
tion factors GATA1, TAL1, or KLF1 [41]. In our work, we
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dissected the regulation control of HOTAIRM1 by PU.1.
Since PU.1 is prominent in myeloid cells, increases during
myeloid differentiation, and achieves the highest level in
mature granulocytes and monocytes [42], our results pro-
vide a reason to explain the high tissue specificity of
HOTAIRM1 in myeloid cells. To fully explain the myeloid
specificity of HOTAIRM1, more studies will be done to
learn the whole picture of the combinational and coordi-
nated regulation of HOTAIRM1 by other tissue-restricted
transcription factors.
Finally, our work revealed the mechanism underlying
the dysregulation of HOTAIRM1 in APL cells. PML-
RARα is a critical factor required for the initiation and
development of APL. At the transcriptional level, PML-
RARα represses genes indispensable for normal gran-
ulocytic differentiation through multiple ways. First,
PML-RARα interferes with the retinoid acid receptor α
(RARα) signaling. As a potent transcriptional repressor,
PML-RARα directly binds to the retinoic acid response
elements (RAREs), recruiting co-repressor proteins
such as DAXX, NcoR, and HDAC1 or methylating en-
zymes such as DNMT1 and DNMT3A, thereby leading
to transcriptional repression [43]. Second, PML-RARα
directly binds to PU.1-RAREh (RARE half ) binding
sites, physically interacts with PU.1, and thus inhibits
PU.1-dependent transactivation of myeloid differentiation-
associated genes, including SPI1 (PU.1), HCK, PSMB10,
and IRF1 [23]. Our study provides an example of the third
scenario, which receives less attention in the past com-
pared to the former two scenarios. We did not observe
the direct binding of PML-RARα in the regulatory re-
gion of HOTAIRM1. Instead, we found that the dysreg-
ulated expression level of HOTAIRM1 was due to the
inhibition of PU.1, which suggested the PML-RARα-
suppressive effect on HOTAIRM1 was indirect. Also,
this explains the noticeably low level of HOTAIRM1 in
APL and suggests that the indirect suppression by
PML-RARα can also be potent. Considering the indis-
pensable role of HOTAIRM1 in myeloid differentiation
[8], our work shows that PML-RARα-indirect inhibition
of HOTIARM1 contributes to the differentiation block
in APL, which provides an additional mechanism for
leukemogenesis in APL.
In conclusion, we identify the lncRNA HOTAIRM1
as a novel PU.1-targeted gene and PU.1 mediates the
myeloid-specific expression of HOTAIRM1. PU.1-
dependent transactivation of HOTAIRM1 relies on the
two PU.1 motifs at the +1100 region of the
HOTAIRM1 promoter. The inhibition of PU.1 by
PML-RARα contributes to the low HOTAIRM1 level
in APL cells, which allows us to understand further
how the oncofusion protein PML-RARα blocks mye-
loid cells at the promyelocytic stage during the devel-
opment of APL.
Materials and methods
Cell culture and reagents
HEK-293T cells were cultured in DMEM (Gibco, Carlsbad,
CA, USA) containing 10 % fetal bovine serum (Moregate
Biotech, Bulimba, QLD, Australia), and NB4, HL60, and
U937 cells were cultured in RPMI 1640 (Gibco) supple-
mented with 10 % fetal bovine serum. Cells were main-
tained at 37 °C in a 5 % CO2 incubator. All-trans retinoic
acid (Sigma-Aldrich, St Louis, MO, USA) was added to
NB4 or U937 cells at a final concentration of 1 μM.
RNA extraction and qRT-PCR
Total RNA was extracted using an RNeasy Mini Kit
(QIAGEN, Hilden, Germany) according to the manufac-
turer’s directions. Reverse transcription was performed
using the SuperScript III Reverse Transcriptase (Invitro-
gen, Carlsbad, CA, USA). Real-time PCR was performed
using the SYBR Green real-time PCR Master Mix
(Toyobo, Osaka, Japan) in the Vii7 Real-Time PCR Sys-
tem (Applied Biosystems Inc., Foster City, CA, USA).
All primers for quantitative reverse transcription-PCR
(qRT-PCR) are listed in Additional file 1: Table S1.
Plasmid construction
The regulatory region of HOTAIRM1 was amplified using
NB4 genomic DNA and then cloned to a pGL3-basic lu-
ciferase reporter vector (Promega, Madison, WI, USA).
The PU.1-coding sequence was amplified using NB4
cDNA and then cloned to the MigR1 vector (Addgene).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was per-
formed according to the Affymetrix protocol as previ-
ously described [44]. The following antibodies were
used: anti-PU.1 (#2258; Cell Signaling Technology,
Danvers, MA, USA), anti-RARα (C-20 X; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and anti-PML
(H238 X; Santa Cruz). All primers for ChIP-qPCR are
listed in Additional file 1: Table S2.
Luciferase reporter assay
Luciferase assays were conducted in HEK-293T cells as
previously described [25]. Dual-luciferase reporter assays
(Promega) were performed 24 h after transfection by Li-
pofectamine 2000 (Invitrogen). Renilla luciferase plas-
mids were used as an internal control for transfection
efficiency correction.
siRNA transfection
The siRNA oligos were transiently transfected to NB4
cells using Nucleofector Kit V (Amaxa Biosystems,
Gaithersburg, MD, USA) according to the manufac-
turer’s instructions. PU.1-targeting siRNA oligos matching
the sequences: CACUCAAGGCUCUUUGCUU (siPU.1
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#1) and GAUGUUACAGGCGUGCAAA (siPU.1 #2), and
a negative control siRNA (AGCGUGUAGCUAGCAG
AGG), were used. After transfection for 24 h, cells were
harvested for qRT-PCR.
Retroviral transduction
The MigR1 vector (Addgene) was used to transduce NB4
cells for PU.1 overexpression. The preparation of retrovi-
ruses and transduction was done as previously described
[45]. Briefly, the MigR1-PU.1 vector and the envelope
plasmids were co-transfected into HEK-293T cells. After
48 h, retroviral supernatants were collected for transduc-
tion. NB4 cells were harvested at 48 h post-transduction.
Gene expression analysis
The transcriptome data was provided by Tomasson et al.
[34] (GSE10358). Robust multi-array average (RMA) [46]
was used to calculate the expression level of HOTAIRM1
and PU.1.
Additional file
Additional file 1: Figure S1. Arsenic trioxide had minimal effect on the
expression levels of HOTAIRM1 and PU.1. Table S1: Primers for RT-qPCR.
Table S2: Primers for ChIP-qPCR. (DOCX 35 kb)
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